Abstract
The amyloidoses are protein-misfolding diseases caused by a precursor protein that undergoes a conformational change, which in turn triggers the formation of amyloid fibrils that damage different organs. Amyloidosis can be either localized or systemic. The systemic amyloidoses can be manifested clinically in many organs, most notably the heart, kidneys, liver, peripheral nerves, skin, gastrointestinal tract, and the microvasculature of the brain. Diagnosis can be confirmed by mass spectrometry or immunoelectron microscopy (for unequivocal amyloid typing) of a Congo red-positive tissue biopsy of clinically involved organs or surrogate tissue, such as subcutaneous fat pad or bone marrow. The amyloidoses are not common and their presenting symptoms may be missed or confused with other clinical entities. For light chain amyloidosis, current therapy produces response rates of about 70% and median survival upward of 5 years.
| Original language | English (US) |
|---|---|
| Title of host publication | Goldman-Cecil Medicine, 27th Edition |
| Subtitle of host publication | Volume 1-2 |
| Publisher | Elsevier |
| Pages | 1305-1310.e1 |
| Volume | 1 |
| ISBN (Electronic) | 9780323930383 |
| ISBN (Print) | 9780323930390 |
| DOIs | |
| State | Published - Jan 1 2023 |
Keywords
- amyloidosis
- light chain
- monoclonal immunoglobulin
- nephrotic syndrome
- restrictive cardiomyopathy
- stem cell transplant
ASJC Scopus subject areas
- General Medicine
Fingerprint
Dive into the research topics of 'Amyloidosis'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS